Search Results - "Link, John O."

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection by Link, John O., Taylor, James G., Xu, Lianhong, Mitchell, Michael, Guo, Hongyan, Liu, Hongtao, Kato, Darryl, Kirschberg, Thorsten, Sun, Jianyu, Squires, Neil, Parrish, Jay, Keller, Terry, Yang, Zheng-Yu, Yang, Chris, Matles, Mike, Wang, Yujin, Wang, Kelly, Cheng, Guofeng, Tian, Yang, Mogalian, Erik, Mondou, Elsa, Cornpropst, Melanie, Perry, Jason, Desai, Manoj C.

“…A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]azabicyclic ring system was…”
Get full text

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein by Lawitz, Eric J, Dvory-Sobol, Hadas, Doehle, Brian P, Worth, Angela S, McNally, John, Brainard, Diana M, Link, John O, Miller, Michael D, Mo, Hongmei

“…Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to…”
Get full text

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi by Taylor, James G., Zipfel, Sheila, Ramey, Kyla, Vivian, Randy, Schrier, Adam, Karki, Kapil K., Katana, Ashley, Kato, Darryl, Kobayashi, Tetsuya, Martinez, Ruben, Sangi, Michael, Siegel, Dustin, Tran, Chinh V., Yang, Zheng-Yu, Zablocki, Jeff, Yang, Cheng Y., Wang, Yujin, Wang, Kelly, Chan, Katie, Barauskas, Ona, Cheng, Guofeng, Jin, Debi, Schultz, Brian E., Appleby, Todd, Villaseñor, Armando G., Link, John O.

“…[Display omitted] Treatment of hepatitis C virus (HCV) infection has been historically challenging due the high viral genetic complexity wherein there are…”
Get full text

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent by Kwon, Hyock Joo, Xing, Weimei, Chan, Katie, Niedziela-Majka, Anita, Brendza, Katherine M, Kirschberg, Thorsten, Kato, Darryl, Link, John O, Cheng, Guofeng, Liu, Xiaohong, Sakowicz, Roman

“…Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its…”
Get full text

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa by Link, John O., Taylor, James G., Trejo-Martin, Alejandra, Kato, Darryl, Katana, Ashley A., Krygowski, Evan S., Yang, Zheng-Yu, Zipfel, Sheila, Cottell, Jeromy J., Bacon, Elizabeth M., Tran, Chinh V., Yang, Cheng Y., Wang, Yujin, Wang, Kelly W., Zhao, Guangyu, Cheng, Guofeng, Tian, Yang, Gong, Ruoyu, Lee, Yu-Jen, Yu, Mei, Gorman, Eric, Mogalian, Erik, Perry, Jason K.

“…[Display omitted] Direct-acting antiviral inhibitors have revolutionized the treatment of hepatitis C virus (HCV) infected patients. Herein is described the…”
Get full text

Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection by Link, John O, Taylor, James G, Xu, Lianhong, Mitchell, Michael, Guo, Hongyan, Liu, Hongtao, Kato, Darryl, Kirschberg, Thorsten, Sun, Jianyu, Squires, Neil, Parrish, Jay, Kellar, Terry, Yang, Zheng-Yu, Yang, Chris, Matles, Mike, Wang, Yujin, Wang, Kelly, Cheng, Guofeng, Tian, Yang, Mogalian, Erik, Mondou, Elsa, Cornpropst, Melanie, Perry, Jason, Desai, Manoj C

Get full text

A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model by Yant, Stephen R., Mulato, Andrew, Hansen, Derek, Tse, Winston C., Niedziela-Majka, Anita, Zhang, Jennifer R., Stepan, George J., Jin, Debi, Wong, Melanie H., Perreira, Jill M., Singer, Eric, Papalia, Giuseppe A., Hu, Eric Y., Zheng, Jim, Lu, Bing, Schroeder, Scott D., Chou, Kevin, Ahmadyar, Shekeba, Liclican, Albert, Yu, Helen, Novikov, Nikolai, Paoli, Eric, Gonik, Daniel, Ram, Renee R., Hung, Magdeleine, McDougall, William M., Brass, Abraham L., Sundquist, Wesley I., Cihlar, Tomas, Link, John O.

“…People living with HIV (PLWH) have expressed concern about the life-long burden and stigma associated with taking pills daily and can experience medication…”
Get full text

Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway by Zheng, Jim, Lu, Bing, Carr, Gavin, Mwangi, Judy, Wang, Kelly, Hao, Jia, Staiger, Kelly McLennan, Kozon, Nathan, Murray, Bernard P, Bashir, Mohammad, Gohdes, Mark A, Tse, Winston C, Schroeder, Scott, Graupe, Michael, Link, John O, Yoon, Jungjoo, Chiu, Anna, Rowe, William, Smith, Bill J, Subramanian, Raju

“…Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few Food and Drug…”
Get more information

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C by Lawitz, Eric J, Gruener, Daniel, Hill, John M, Marbury, Thomas, Moorehead, Lisa, Mathias, Anita, Cheng, Guofeng, Link, John O, Wong, Kelly A, Mo, Hongmei, McHutchison, John G, Brainard, Diana M

“…Background & Aims GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype 1 HCV replicons. The safety,…”
Get full text

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir by Cheng, Guofeng, Tian, Yang, Doehle, Brian, Peng, Betty, Corsa, Amoreena, Lee, Yu-Jen, Gong, Ruoyu, Yu, Mei, Han, Bin, Xu, Simin, Dvory-Sobol, Hadas, Perron, Michel, Xu, Yili, Mo, Hongmei, Pagratis, Nikos, Link, John O, Delaney, William

“…Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV)…”
Get full text

A general, catalytic, and enantioselective synthesis of .alpha.-amino acids by Corey, E. J, Link, John O

Get full text

Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873 by Kato, Darryl, Choy, Regina Wai-Yan, Canales, Eda, Dick, Ryan A., Lake, April D., Shapiro, Nathan D., Chin, Elbert, Li, Jiayao, Zhang, Jennifer R., Wu, Qiaoyin, Saito, Roland D., Metobo, Sammy, Aktoudianakis, Evangelos, Schroeder, Scott D., Yang, Zheng-Yu, Glatt, Dylan M., Balsitis, Scott, Gamelin, Lindsay, Yu, Mei, Cheng, Guofeng, Delaney, William E., Link, John O.

“…Chronic hepatitis B (CHB) virus infection afflicts hundreds of millions of people and causes nearly one million deaths annually. The high levels of circulating…”
Get full text

A catalytic enantioselective synthesis of denopamine, a useful drug for congestive heart failure by Corey, E. J, Link, John O

Get full text

539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans by Zheng, Jim, Yant, Stephen R, Ahmadyar, Shekeba, Chan, Tiffany Y, Chiu, Anna, Cihlar, Tomas, Link, John O, Lu, Bing, Mwangi, Judy, Rowe, William, Schroeder, Scott D, Stepan, George J, Wang, Kelly Wei, Subramanian, Raju, Tse, Winston C

Get full text

Asymmetric Synthesis and Stereochemical Assignment of RS-97613, a Potent Immunosuppressive and Antiinflammatory Agent by Smith, David B, Waltos, Ann Marie, Loughhead, David G, Weikert, Robert J, Morgans, David J, Rohloff, John C, Link, John O, Zhu, Rong-rong

Get full text

Trapping of an IMP Dehydrogenase−Substrate Covalent Intermediate by Mycophenolic Acid by Link, John O, Straub, Kenneth

Get full text

Clinical targeting of HIV capsid protein with a long-acting small molecule by Link, John O., Rhee, Martin S., Tse, Winston C., Zheng, Jim, Somoza, John R., Rowe, William, Begley, Rebecca, Chiu, Anna, Mulato, Andrew, Hansen, Derek, Singer, Eric, Tsai, Luong K., Bam, Rujuta A., Chou, Chien-Hung, Canales, Eda, Brizgys, Gediminas, Zhang, Jennifer R., Li, Jiayao, Graupe, Michael, Morganelli, Philip, Liu, Qi, Wu, Qiaoyin, Halcomb, Randall L., Saito, Roland D., Schroeder, Scott D., Lazerwith, Scott E., Bondy, Steven, Jin, Debi, Hung, Magdeleine, Novikov, Nikolai, Liu, Xiaohong, Villaseñor, Armando G., Cannizzaro, Carina E., Hu, Eric Y., Anderson, Robert L., Appleby, Todd C., Lu, Bing, Mwangi, Judy, Liclican, Albert, Niedziela-Majka, Anita, Papalia, Giuseppe A., Wong, Melanie H., Leavitt, Stephanie A., Xu, Yili, Koditek, David, Stepan, George J., Yu, Helen, Pagratis, Nikos, Clancy, Sheila, Ahmadyar, Shekeba, Cai, Terrence Z., Sellers, Scott, Wolckenhauer, Scott A., Ling, John, Callebaut, Christian, Margot, Nicolas, Ram, Renee R., Liu, Ya-Pei, Hyland, Rob, Sinclair, Gary I., Ruane, Peter J., Crofoot, Gordon E., McDonald, Cheryl K., Brainard, Diana M., Lad, Latesh, Swaminathan, Swami, Sundquist, Wesley I., Sakowicz, Roman, Chester, Anne E., Lee, William E., Daar, Eric S., Yant, Stephen R., Cihlar, Tomas

“…Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis 1…”
Get full text

Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease by Dhanak, Dashyant, Burton, George, Christmann, Lisa T, Darcy, Michael G, Elrod, Kyle C, Kaura, Arun, Keenan, Richard M, Link, John O, Peishoff, Catherine E, Shah, Dinubhai H

“…A versatile synthetic route to a novel series of bis-imidazolemethanes designed to inhibit the hCMV protease has been developed and a series of potential metal…”
Get full text

Advances in cathepsin S inhibitor design by Link, John O, Zipfel, Sheila

“…Cathepsin S is expressed in antigen-presenting cells and plays a role in invariant chain processing and major histocompatibility complex class II (MHCII)…”
Get more information

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent: e0122844 by Kwon, Hyock Joo, Xing, Weimei, Chan, Katie, Niedziela-Majka, Anita, Brendza, Katherine M, Kirschberg, Thorsten, Kato, Darryl, Link, John O, Cheng, Guofeng, Liu, Xiaohong

“…Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its…”
Get full text